Cormedix Inc (CRMD) Stock Price, Quote & News

Company Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was in...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 517 9500

Website: cormedix.com

Address:

389 Interpace Pkwy, Suite 450, Parsippany, United States

Derek22us Aug. 4 at 1:39 PM

$CRMD SwineOfEastpoop.........Short Sheister.

0 · Reply

wolfofwestloop Aug. 4 at 1:27 PM

$CRMD What a complete waste of 12 months....

0 · Reply

Noname2022 Aug. 4 at 11:57 AM

$CRMD $FMS “As already indicated, we are beginning to see the impact of our catheter-related- bloodstream infection prevention efforts. We saw a 23% reduction in bloodstream infections over the past year, which supports lower infection- related hospitalizations and also translates into lower patient mortality risk” https://stockanalysis.com/quote/etr/FME/transcripts/552777-q2-2026/

0 · Reply

Noname2022 Aug. 4 at 2:57 AM

$CRMD $FMS Just posting for awarness - New CEO of care delivery for Fresenius who started 8.1.26. https://freseniusmedicalcare.com/en/media/newsroom/fresenius-medical-care-appoints-cassie-mclean-as-new-management-board-member-for-care-delivery/?utm_source=linkedin&utm_medium=organic_social&utm_campaign=03_august2026_caredelivery_announcement&utm_content=corporate

0 · Reply

altair787 Aug. 3 at 11:57 PM

$CRMD Moving closer to earnings and moving lower, wow!

1 · Reply

Noname2022 Aug. 3 at 11:32 PM

$CRMD One of the NAD roles filled!

0 · Reply

Noname2022 Aug. 3 at 9:09 PM

$CRMD $DVA $FMS $AKBA https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q2/FME_Q2_2026_Analyst_Presentation.pdf

1 · Reply

wolfofwestloop Aug. 3 at 9:08 PM

$CRMD I'm so tired of this POS! It's always something with this one...

1 · Reply

Noname2022 Aug. 3 at 8:28 PM

$CRMD $AKBA $FMS $DVA

0 · Reply

Derek22us Aug. 3 at 6:46 PM

$CRMD Disgusting gutless low IQ short enabling selling scum.

1 · Reply

CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026

2026-07-07T11:30:10.000Z - 4 weeks ago

CorMedix price target lowered to $13 from $14 at RBC Capital

Jun 23, 2026, 9:00 AM EDT - 6 weeks ago

CorMedix Transcript: AGM 2026

2026-06-08T13:00:11.000Z - 2 months ago

CorMedix announces United States Court of Appeals affirms patent judgements

Jun 8, 2026, 8:30 AM EDT - 2 months ago

U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation

Jun 3, 2026, 4:20 PM EDT - 2 months ago

CorMedix Transcript: Jefferies Global Healthcare Conference 2026

May 22, 2026, 7:00 AM EDT - 2 months ago

CorMedix Slides: Corporate presentation

May 20, 2026, 11:00 AM EDT - 2 months ago

CorMedix Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 15, 2026, 8:30 AM EDT - 2 months ago

Cormedix Therapeutics to Participate in two Upcoming Investor Conferences

May 14, 2026, 8:30 AM EDT - 2 months ago

CorMedix Earnings Call Transcript: Q1 2026

May 14, 2026, 8:30 AM EDT - 2 months ago

CorMedix Earnings release: Q1 2026

May 14, 2026, 8:30 AM EDT - 2 months ago

CorMedix Quarterly report: Q1 2026

2026-05-14T11:53:51.000Z - 2 months ago

CorMedix reports Q1 EPS 43c, consensus 33c

2026-05-14T11:47:54.000Z - 2 months ago

CorMedix raises FY26 revenue view to $325M-$345M from $300M-$320M

May 14, 2026, 7:30 AM EDT - 2 months ago

Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026, 8:30 AM EDT - 3 months ago

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

CorMedix Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

CorMedix Proxy statement: Proxy filing

2026-04-28T19:40:19.000Z - 3 months ago

Citizens healthcare analysts hold an analyst/industry conference call

2026-04-28T11:56:23.000Z - 3 months ago

CorMedix price target raised to $14 from $13 at RBC Capital

2026-04-27T12:05:37.000Z - 3 months ago

CorMedix announces ReSPECT clinical trial met primary endpoint

Apr 27, 2026, 7:30 AM EDT - 3 months ago

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

Apr 17, 2026, 8:00 AM EDT - 3 months ago

CorMedix Proxy statement: Proxy filing

Apr 14, 2026, 3:00 PM EDT - 3 months ago

CorMedix Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 8:30 AM EDT - 4 months ago

CorMedix to Participate in Needham Virtual Healthcare Conference

Mar 11, 2026, 9:35 AM EDT - 5 months ago

CorMedix Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 1:00 PM EDT - 5 months ago

CorMedix Transcript: Leerink Global Healthcare Conference 2026

Mar 7, 2026, 6:00 AM EST - 5 months ago

CorMedix Slides: Corporate presentation

2026-03-06T22:20:58.000Z - 5 months ago

CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M

2026-03-06T17:05:52.000Z - 5 months ago

CorMedix price target lowered to $13 from $15 at Leerink

Mar 5, 2026, 12:58 PM EST - 5 months ago

CorMedix stock drops after earnings: is this dip a buy before key catalyst?

Mar 5, 2026, 8:30 AM EST - 5 months ago

CorMedix Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 5 months ago

CorMedix Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 5 months ago

CorMedix Earnings release: Q4 2025

2026-03-05T12:36:24.000Z - 5 months ago

CorMedix reports Q4 EPS 16c vs 20c last year

Mar 5, 2026, 7:30 AM EST - 5 months ago

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 2, 2026, 8:30 AM EST - 5 months ago

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

Feb 12, 2026, 8:30 AM EST - 6 months ago

CorMedix to Participate in Upcoming Investor Conferences

Feb 10, 2026, 1:00 PM EST - 6 months ago

CorMedix Transcript: Investor Day 2026

Feb 10, 2026, 1:00 PM EST - 6 months ago

CorMedix Slides: FY 2026

2026-02-02T13:35:15.000Z - 6 months ago

CorMedix board authorizes share repurchase program of up to $75M

Feb 2, 2026, 8:30 AM EST - 6 months ago

CorMedix Therapeutics Announces Share Repurchase Program

Jan 29, 2026, 8:30 AM EST - 6 months ago

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

2026-01-23T11:10:42.000Z - 6 months ago

CorMedix price target lowered to $13 from $18 at H.C. Wainwright

2026-01-21T11:35:46.000Z - 6 months ago

CorMedix price target lowered to $13 from $22 at RBC Capital

Jan 12, 2026, 7:30 PM EST - 7 months ago

CorMedix Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 10, 2026, 7:00 AM EST - 7 months ago

CorMedix Slides: Corporate presentation

Jan 9, 2026, 8:30 AM EST - 7 months ago

CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 1:37 PM EST - 7 months ago

Why is CorMedix stock crashing today: is it worth buying on the dip?

2026-01-08T17:45:22.000Z - 7 months ago

CorMedix price target lowered to $16 from $20 at Truist

Jan 8, 2026, 8:05 AM EST - 7 months ago

CorMedix Therapeutics Announces Leadership and Board Updates

Jan 8, 2026, 8:00 AM EST - 7 months ago

CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

Dec 18, 2025, 8:00 AM EST - 8 months ago

CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

Nov 12, 2025, 4:05 PM EST - 9 months ago

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

TLPH

Nov 12, 2025, 8:30 AM EST - 9 months ago

CorMedix Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 9 months ago

CorMedix Quarterly report: Q3 2025

Nov 12, 2025, 8:30 AM EST - 9 months ago

CorMedix Earnings release: Q3 2025

Nov 12, 2025, 7:30 AM EST - 9 months ago

CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

Oct 31, 2025, 8:30 AM EDT - 9 months ago

CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

Oct 24, 2025, 8:00 AM EDT - 10 months ago

CorMedix Proxy statement: Proxy Filing

Oct 23, 2025, 8:30 AM EDT - 10 months ago

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath

Oct 22, 2025, 4:05 PM EDT - 10 months ago

Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 20, 2025, 9:42 AM EDT - 10 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC RANI RAPT

Oct 20, 2025, 7:30 AM EDT - 10 months ago

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance

Oct 14, 2025, 8:00 AM EDT - 10 months ago

CorMedix Proxy statement: Proxy Filing

Sep 30, 2025, 8:00 AM EDT - 11 months ago

CorMedix Registration statement: Registration Filing

Sep 29, 2025, 8:30 AM EDT - 11 months ago

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO

Sep 15, 2025, 8:00 AM EDT - 11 months ago

CorMedix Proxy statement: Proxy Filing

Sep 10, 2025, 10:45 AM EDT - 11 months ago

CorMedix Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 8:30 AM EDT - 11 months ago

CorMedix Announces Strategic Minority Investment in Talphera

TLPH

Sep 8, 2025, 8:30 AM EDT - 11 months ago

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

TLPH

Sep 5, 2025, 8:35 AM EDT - 11 months ago

CorMedix Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 1 year ago

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

Aug 7, 2025, 10:49 AM EDT - 1 year ago

CorMedix to Buy Melinta Therapeutics for $300 Million

Aug 7, 2025, 7:30 AM EDT - 1 year ago

CorMedix Quarterly report: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 1 year ago

CorMedix Earnings release: Q2 2025

Aug 7, 2025, 7:10 AM EDT - 1 year ago

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

Aug 7, 2025, 7:00 AM EDT - 1 year ago

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 27, 2025, 8:00 AM EDT - 1 year ago

CorMedix Inc. Announces Pricing of Public Offering of Common Stock

Jun 26, 2025, 4:01 PM EDT - 1 year ago

CorMedix Inc. Announces Proposed Public Offering of Common Stock

Jun 23, 2025, 7:30 AM EDT - 1 year ago

CorMedix inc. Announces Customer Implementation

Jun 5, 2025, 3:45 PM EDT - 1 year ago

CorMedix Transcript: Jefferies Global Healthcare Conference 2025

May 30, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

May 21, 2025, 3:05 PM EDT - 1 year ago

CorMedix Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Participate in the RBC Global Healthcare Conference

May 8, 2025, 11:00 AM EDT - 1 year ago

CorMedix Transcript: The Citizens JMP Life Sciences Conference 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Earnings release: Q1 2025

May 6, 2025, 7:30 AM EDT - 1 year ago

CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 29, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CorMedix Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CorMedix Proxy statement: Proxy Filing

Apr 8, 2025, 2:15 PM EDT - 1 year ago

CorMedix Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 7:30 AM EDT - 1 year ago

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

Apr 2, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

Derek22us Aug. 4 at 1:39 PM

$CRMD SwineOfEastpoop.........Short Sheister.

0 · Reply

wolfofwestloop Aug. 4 at 1:27 PM

$CRMD What a complete waste of 12 months....

0 · Reply

Noname2022 Aug. 4 at 11:57 AM

0 · Reply

Noname2022 Aug. 4 at 2:57 AM

0 · Reply

altair787 Aug. 3 at 11:57 PM

$CRMD Moving closer to earnings and moving lower, wow!

1 · Reply

Noname2022 Aug. 3 at 11:32 PM

$CRMD One of the NAD roles filled!

0 · Reply

Noname2022 Aug. 3 at 9:09 PM

$CRMD $DVA $FMS $AKBA https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q2/FME_Q2_2026_Analyst_Presentation.pdf

1 · Reply

wolfofwestloop Aug. 3 at 9:08 PM

$CRMD I'm so tired of this POS! It's always something with this one...

1 · Reply

Noname2022 Aug. 3 at 8:28 PM

$CRMD $AKBA $FMS $DVA

0 · Reply

Derek22us Aug. 3 at 6:46 PM

$CRMD Disgusting gutless low IQ short enabling selling scum.

1 · Reply

Noname2022 Aug. 3 at 6:31 PM

$CRMD $FMS Fresenius Q2 math: Implied incremental TDAPA benefit: €42.7M ≈ $49.7M at $1.163/€ Q2 reimbursement: $4.741/unit × 30 units/vial = $142.23/vial 2 vials/session × 3 sessions/week × 13 weeks = 78 vials/patient 78 × $142.23 = $11,094 reimbursement/patient $49.7M ÷ $11,094 = ~4,480 patients minimum

1 · Reply

Noname2022 Aug. 3 at 6:09 PM

$CRMD $FMS Fresenius Q2 financials imply approximately €42.7M of incremental TDAPA benefit above the phosphate-binder contribution already included in Q2 2025. With phosphate binders likely flat to slightly down YoY, that points to roughly €45M from DefenCath in Q2—right in line with expectations. https://freseniusmedicalcare.com/en/media/newsroom/q2-2026/?utm_source=linkedin&utm_medium=organic_social&utm_campaign=03_august2026_q2_financieal_earnings&utm_content=helen https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q2/FME_Q2_2026_Financial_Tables.pdf

0 · Reply

Ycapital Aug. 3 at 4:35 PM

$CRMD I’m starting my position and gradually adding as it moves slowly toward the gap.

1 · Reply

Derek22us Aug. 3 at 3:58 PM

$CRMD Free trading does not exist with this stock, the share price is being held hostage by those who have derivative positions in 15 Million "borrowed" shares.

1 · Reply

btdb Aug. 3 at 11:45 AM

$CRMD

0 · Reply

Maissessap Aug. 3 at 7:43 AM

$CRMD The FPER is 85 times ....

0 · Reply

Maissessap Aug. 3 at 5:52 AM

$CRMD PER is the past, think about FPER ....

0 · Reply

drew64 Aug. 3 at 12:47 AM

$CRMD Tough year? With a P/E of 3.42 I foresee many good years going forward🤙🏼🍻😎

1 · Reply

Noname2022 Aug. 2 at 9:28 PM

$CRMD 2nd ABD filled! (Returning from Syneos I believe)

0 · Reply

REZZAYO Aug. 2 at 8:51 PM

$CRMD Vori, Cresemba all sold off label in Prophy settings, I don’t see why Rezzayo can’t start selling in Prophylactic setting pre sNDA and FDA Label once the Team is fully assembled and deployed

0 · Reply

Noname2022 Aug. 2 at 8:19 PM

$CRMD Rezzayo prophy sNDA and revenue estimates *ChatGPT Sol 5.6 High

0 · Reply

Noname2022 Aug. 2 at 1:06 PM

$CRMD $ICUI $DVA $FMS Clearguard HD: guessing DVA contract & best guess at access trends based on their marketing data (Fresenius uses both Clearguard HD & Defencath!) On the Q2 2024 call, ICU Medical said it had: “recently signed a multi-year committed agreement with a leading U.S. operator of dialysis clinics” Management said the agreement would expand its evidence base and help attract other dialysis operators. https://stockanalysis.com/stocks/icui/transcripts/192237-q2-2024/

0 · Reply

Market Cap	590.74M
Revenue (ttm)	311.71M
Net Income (ttm)	163.06M
EPS (ttm)	N/A
PE Ratio	3.96
Forward PE	14.69
Profit Margin	52.31%
Debt to Equity Ratio	0.00

Volume	856,100
Avg Vol	1,228,054
Day's Range	N/A - N/A
Shares Out	78.45M
Stochastic %K	39%
Beta	1.48
Analysts	Strong Sell
Price Target	$13.86